Chemokine Networks in Cutaneous T Cell Lymphoma: Tumor Microenvironment Remodeling and Therapeutic Targets
Open Access
- 13 January 2026
- journal article
- review article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (1) , 79
Abstract
Cutaneous T-cell lymphoma (CTCL) is a heterogeneous malignancy characterized by the proliferation of skin-homing CD4+ T cells and profound immune dysregulation within the tumor microenvironment (TME). This review synthesizes evidence on chemokine–receptor networks that govern malignant T-cell trafficking among blood, skin, and lymph nodes, the formation of immunosuppressive niches, and clinically actionable biomarker candidates. Among the best-supported axes, CCL17/CCL22–CCR4 and CCL27/CCL28–CCR10 mediate skin tropism, CCL19/CCL21–CCR7 contributes to lymph node homing, and CXCL12–CXCR4 supports skin trafficking and is associated with disease progression. In contrast, CCR2/CCR5/CCR6/CCR8-centered circuits and CXCR3/CXCR5 pathways are emerging regulators of myeloid recruitment, regulatory T-cell accumulation, and context-dependent immune activation. Therapeutically, agents targeting chemokine pathways, most notably the CCR4 monoclonal antibody Mogamulizumab, have demonstrated clinical efficacy, while emerging inhibitors of CCR6, CCR5, and CXCR4 offer promising avenues for intervention. We further highlight how recent single-cell and other high-dimensional omics studies refine cell-type–specific chemokine sources and receptor expression, enabling more precise mapping of chemokine-driven intercellular communication programs in CTCL TME remodeling and better prioritization of therapeutic targets and biomarkers.Keywords
This publication has 116 references indexed in Scilit:
- Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell LymphomaCurrent Oncology Reports, 2025
- Unveiling the Hidden Struggles: Exploring the Profound Impact of Advanced Stage Cutaneous T-Cell Lymphoma on Quality of LifeSkin Health and Disease, 2023
- What Is New in Cutaneous T Cell Lymphoma?Current Oncology Reports, 2023
- Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2022
- CCR4 in cutaneous T‐cell lymphoma: Therapeutic targeting of a pathogenic driverEuropean Journal of Immunology, 2021
- GATA‐3 in T‐cell lymphoproliferative disordersIUBMB Life, 2019
- Cutaneous lymphomas—An update 2019Hematological Oncology, 2019
- Malignant inflammation in cutaneous T‐cell lymphoma—a hostile takeoverSeminars in Immunopathology, 2016
- Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cellsEuropean Journal of Immunology, 2005
- CCR10 is expressed in cutaneous T‐cell lymphomaInternational Journal of Cancer, 2005